View : 41 Download: 0
Inhibition of osteoclast differentiation and bone resorption by a novel lysophosphatidylcholine derivative, SCOH
- Inhibition of osteoclast differentiation and bone resorption by a novel lysophosphatidylcholine derivative, SCOH
- Kwak H.B.; Lee S.W.; Li Y.-J.; Kim Y.-A.; Han S.-Y.; Jhon G.-J.; Kim H.-H.; Lee Z.H.
- Ewha Authors
- 전길자; 한소엽
- SCOPUS Author ID
- 전길자; 한소엽
- Issue Date
- Journal Title
- Biochemical Pharmacology
- vol. 67, no. 7, pp. 1239 - 1248
- SCI; SCIE; SCOPUS
- Osteoclasts are multinucleated cells formed by multiple steps of cell differentiation from progenitor cells of hematopoietic origin. Intervention in osteoclast differentiation is considered as an effective therapeutic approach to the treatment for bone diseases involving osteoclasts. In this study, we found that the organic compound (S)-1-lyso-2-stearoylamino-2-deoxy-sn-glycero-3- phosphatidylcholine (SCOH) inhibited osteoclast differentiation. The inhibitory effect of SCOH was observed in mouse bone marrow cell cultures supported either by coculturing with osteoblasts or by adding macrophage colony stimulating factor (M-CSF) and receptor activator of nuclear factor κB ligand (RANKL). M-CSF and RANKL activate the ERK, Akt, and NF-κB signal transduction pathways, and SCOH suppressed this activation. SCOH also inhibited the bone resorptive activity of differentiated osteoclasts. It attenuated bone resorption, actin ring formation, and survival of mature osteoclasts. Reduced activation of Akt and NF-κB and decreased induction of XIAP were observed in mature osteoclasts treated with SCOH. Thus, this novel phosphatidylcholine derivative may be useful for treating bone-resorption diseases. © 2004 Elsevier Inc. All rights reserved.
- Appears in Collections:
- 자연과학대학 > 화학·나노과학전공 > Journal papers
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.